Famous Patents
The ice cream cone was invented at the St. Louis Worlds Fair by Ernest Hamwi in 1904. His waffle booth was next to an ice cream vendor who ran short of dishes. Hamwi rolled a waffle to hold ice cream and the cone was born.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7838006 | Viral vaccine composition, process and methods of use A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologicall... | 11/23/2010 |
| 7582303 | Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products suc... | 09/01/2009 |
| 7378234 | Method for isolating hepatitis C virus peptides Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said... | 05/27/2008 |
| 7285289 | Nanoparticle vaccines The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also displa... | 10/23/2007 |
| 7252827 | Conserved motif of hepatitis C virus E2/NS1 region Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/07/2007 |
| 7244422 | Vaccines containing ribavirin and methods of use thereof The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribav... | 07/17/2007 |
| 7244715 | Vaccines containing ribavirin and methods of use thereof Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope presen... | 07/17/2007 |
| 7208523 | Alanine- and glycine-containing therapeutic agent for hepatitis The therapeutic agent for hepatitis, containing alanine and glycine, has only a slight toxicity and it can be administered either orally or intravenously to improve the liver function. ... | 04/24/2007 |
| 7204989 | HEV antigenic peptide and methods A highly immunoreactive viral peptide, pE2, is disclosed which is derived from the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants ... | 04/17/2007 |
| 7148323 | Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus The invention describes the identification of a major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the is... | 12/12/2006 |
| 7037506 | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry The present invention provides a vaccine accelerator factor (VAF) which is an in ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragme... | 05/02/2006 |
| 7029678 | Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses. ... | 04/18/2006 |
| 7005130 | Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products suc... | 02/28/2006 |
| 6932972 | Combined vaccine compositions Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen... | 08/23/2005 |
| 6893644 | Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A ... | 05/17/2005 |
| 6887484 | Vaccine composition containing a promoter peptide A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a p... | 05/03/2005 |
| 6881821 | Hepatitis-C virus type 4, 5, and 6 Newly elucidated sequences of hepatitis C virus type 4 and type 5 are described, together with those of a newly discovered type 6. Unique type-specific sequences in the NS4, NS5 and core regions enable HCV detection and genotyping into types 1 to 6. Antigenic peptid... | 04/19/2005 |
| 6849429 | Viral pseudo-capsids including assembly agonists and antagonists Recombinant hepatitis C virus (HCV) capsid proteins that self-assemble into large spherical virus-like particles structures and viral capsids that include conformational antigenic epitopes are provided. The large spherical virus-like particles structures and viral c... | 02/01/2005 |
| 6828139 | Production of replicative hepatitis C virus A nucleic acid having a first nucleotide sequence encoding an infectious hepatitis C virus, a second nucleotide sequence encoding a ribozyme, and an inducible promoter operably linked to the first and second nucleotide sequences, the ribozyme being configured to rem... | 12/07/2004 |
| 6706873 | Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open ... | 03/16/2004 |
| 6680059 | Vaccines containing ribavirin and methods of use thereof The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions h... | 01/20/2004 |
| 6623739 | Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.... | 09/23/2003 |
| 6596282 | Treatment of chronic viral infections with M. vaccae The present invention provides the use of an M. vaccae preparation for the manufacture of a medicament for use in the treatment of a chronic viral infection, excluding an HIV infection. Chronic viral infections include HPV infection, such as HPV infection... | 07/22/2003 |
| 6586568 | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bi... | 07/01/2003 |
| 6534064 | Stabilized protein particles for inducing cellular immune responses A method for producing a cellular immune response in a vertebrate subject comprising administering to the vertebrate subject a vaccine composition comprising a protein particle antigen and a pharmaceutically acceptable excipient is disclosed.... | 03/18/2003 |
| 6524589 | Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same The invention relates to the purification and crystallization of hepatitis C virus (HCV) NS3/NS4A polypeptide complex. Also, crystallization conditions for NS3/NS4A are provided. Further, the atomic coordinates for the NS3/NS4A protein are disclosed. Exam... | 02/25/2003 |
| 6488934 | Hepatitis B vaccine A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.... | 12/03/2002 |
| 6451320 | Combined hepatitis and herpesvirus antigen compositions Novel combined vaccine compositions preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatit... | 09/17/2002 |
| 6447994 | Production of replicative hepatitis C virus A nucleic acid having a first nucleotide sequence encoding an infectious hepatitis C virus, a second nucleotide sequence encoding a ribozyme, and an inducible promoter operably linked to the first and second nucleotide sequences, the ribozyme being config... | 09/10/2002 |
| 6410009 | Pharmaceutical composition for treating hepatitis B virus (HBV) infection The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hep... | 06/25/2002 |
| 6299874 | Method of treatment A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor... | 10/09/2001 |
| 6287759 | Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, desig... | 09/11/2001 |
| 6261569 | Retro-, inverso- and retro-inverso synthetic peptide analogues Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce... | 07/17/2001 |
| 6217858 | Pharmaceutical composition for treating hepatitis B virus (HBV) infection The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hep... | 04/17/2001 |
| 6210901 | Specific binding substances for antibodies and their use for immunoassays or vaccines The invention relates to derivatives of hepatitis C virus amino acid sequences. These derivatives can be used to screen samples, such as blood, to determine if antibodies to hepatitis C virus are present.... | 04/03/2001 |
| 6153579 | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex The present invention relates to compositions and crystals of a hepatitis C virus protease in complex with its viral cofactor. This invention also relates to methods of using the structure coordinates of hepatitis C virus protease in complex with a synthe... | 11/28/2000 |
| 6146632 | Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.... | 11/14/2000 |
| 6146643 | Human/simian chimeric hepatitis A virus vaccine The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition com... | 11/14/2000 |
| 6136320 | Vaccines expressed in plants The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expressio... | 10/24/2000 |
| 6117449 | Method for inducing a systemic immune response to a hepatitis antigen A method is provided for inducing a systemic immune response to an antigen selected from hepatitis B and hepatitis C antigens in a mammal. The method comprises orally administering lyophilized multilamellar liposomes containing the antigen. The liposomes ... | 09/12/2000 |
